AI-powered biotech Vivodyne aims to end animal testing with $40m funding boost
Longevity Technology - 30-May-2025Biotech firm uses AI and robotics to test drugs on real human tissues, not animals
Join the club for FREE to access the whole archive and other member benefits.
It's surprising how much pharmaceutical research to date has been more art than science. Computing power is still a long way off predicting the properties of proteins and cells from their DNA, so until then the more research that can be accelerated by automation (e.g. lab robots, lab-on-chip) the better.
And this is being driven by the big pharma companies who can't afford the failure rate at late stage drug development, or worse after release which can result in multi-billion law suits. I attended an excellenty talk by the chief scientific office for GE Healthcare recently and they are mass producing stem cell lines, and the machinery to test them, so that drugs can be tested for cardio-toxicity much earlier on in the development process.
Biotech firm uses AI and robotics to test drugs on real human tissues, not animals
Early success is promising, but bigger studies are needed
Insilico’s "Supervisor" robot automates lab work and speeds up drug discovery
AI-powered device enhances efficiency, reduces workload, and ensures precise automated blood draws
Click on resource name for more details.
LabGenius: Cutting through AI hype in drug development
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company.
Nxera Pharma, formerly called Heptares Therapeutics, is a technology powered biopharma company
Company developing drugs for chronic medical conditions relating to abnormalities of bacterial composition
Pioneering a novel discovery platform to radically improve drug development for complex diseases of aging
Reducing the time and cost of clinical tests will help us beat the big killers, then guide our personalised rejuvenation programmes